First Oncode Clinical Proof of Concept (CPoC) project now finalized
News
27 October 2020
First Oncode Clinical Proof of Concept (CPoC) project now finalized
We are happy to announce that our first Oncode CPoC study - a collaboration between Oncode Investigator Jean Paul Medema (Amsterdam UMC) and clinician Henk Verheul (Radboud UMC) titled Pulsatile high dose Sunitinib as a specific drug for (a subset of) metastatic mesenchymal CRCs - is now finalized.
Bianca-OliviaNita
New CPoC grant awarded: researchers and clinicians team up for study on gastroenteropancreatic neuroendocrine tumors (GEPNETs)
News
12 October 2020
New CPoC grant awarded: researchers and clinicians team up for study on gastroenteropancreatic neuroendocrine tumors (GEPNETs)
Oncode Institute keeps investing in bringing insights from basic science into clinical practice. With the 12th grant awarded within the CPoC programme, Oncode Investigator Roland Kanaar together with Oncode researcher Julie Nonnekens (both Erasmus MC) will team up with a group of clinicians, a physicist and pharmacist for a project focused on gastroenteropancreatic neuroendocrine tumors (GEPNETs).
Bianca-OliviaNita
Oncode Facilities & Technologies will add value to your research
News
29 September 2020
Oncode Facilities & Technologies will add value to your research
The goal of Oncode Institute is to translate the results of ground-breaking fundamental research into the clinic faster, in order to improve the chances of cancer patients. Investing in new technologies and facilities - which are available to all Oncode researchers - is one of the ways that Oncode wants to contribute to breakthroughs in cancer research. In this interview Jacqueline Staring, Programme Manager at Oncode Institute, discusses the facilities and technologies that are available for the Oncode research community and how they will support and accelerate oncology research.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics
News
29 September 2020
Official launch of Immagene: Dutch company developing next-generation immuno-oncology therapeutics
Oncode Institute is proud to announce that Immagene B.V. launched this month as a private biotech company, focused on developing next-generation precision immuno-oncology therapeutics. The company announced its launch following a successful fundraise from Oncode Bridge Fund, Swanbridge Capital, and Innovatiefonds Noord Holland.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Beyond Distancing: Science and Community at the Oncode Annual Scientific Meeting
News
23 September 2020
Beyond Distancing: Science and Community at the Oncode Annual Scientific Meeting
The two-day Oncode Annual Scientific Meeting this month was our very first hybrid event. With a full program on both days, around 100 participants present in person each day at the Van Nelle Fabriek in Rotterdam, and more than 230 participants on average online per day, we now look back feeling both proud and relieved. Proud of an event that was successful, and relieved that this has shown that though we do need to respect the rules of social distancing, we don’t have to stay or feel apart.
Bianca-OliviaNita

Meet Oncode

Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
https://www.oncode.nl/about/in-het-nederlands
About
In het Nederlands
Oncode is een internationale organisatie. Maar gezien onze oorsprong vertellen we ons verhaal ook graag in het Nederlands.
https://www.oncode.nl/about
About
Getting acquainted
Whether you're looking for a chart or contact information, and whether you're a PhD, a partner or a patient: pleased to meet you.